NS-089/NCNP-02

Brogidirsen (NS-089/NCNP-02) is a dual-targeting phosphorodiamidate morpholino antisense oligonucleotide co-developed by Nippon Shinyaku's US subsidiary NS Pharma and Japan's National Center of Neurology and Psychiatry (NCNP), aimed at the roughly 6-8% of Duchenne muscular dystrophy patients whose deletion mutations can be corrected by skipping exon 44 of the dystrophin gene [1]. A Phase 2 open-label trial (NCT05996003, n=20) in ambulant boys is active but no longer recruiting, following a completed Phase 1/2 dose-escalation study (NCT04129294) whose published results are the single most important signal for this asset: in the 80 mg/kg weekly cohort, extended 24-week treatment produced mean dystrophin restoration of 24.47% of normal by Western blot, with the 40 mg/kg cohort reaching 16.63% [2][3][4][5][9]. Those numbers materially exceed the roughly 1-5% ceiling that has characterized prior approved PMO exon skippers and approach the 15-20% band suggested by Becker muscular dystrophy biology as clinically meaningful [1]. NS Pharma already has one drug in this class approved: viltolarsen (Viltepso), an exon 53 skipper granted FDA accelerated approval in August 2020 [6]. Brogidirsen has FDA orphan drug, rare pediatric disease, and breakthrough therapy designations [10][11]. Competitor Avidity Biosciences (delpacibart zotadirsen, formerly AOC 1044) is targeting the same exon 44 population with an antibody-oligonucleotide conjugate and has reported up to 25% net increase in dystrophin production with total dystrophin reaching 54-58% of normal in EXPLORE44 [12][13]. The exon 44 class ceiling appears to have already moved above the naked-PMO baseline; brogidirsen and del-zota are the two assets defining the new ceiling.

Novel investigational compound in Phase 2. NCT05996003 is active but not recruiting, with n=20 ambulant boys enrolled [3]. The International Nonproprietary Name brogidirsen has been assigned, and an RxNorm CUI (2687695) is registered in NLM's authoritative drug identifier system. Nippon Shinyaku disclosed that FDA has granted brogidirsen orphan drug designation, rare pediatric disease designation (June 2023), and breakthrough therapy designation (July 2023) [10][11]. Nippon Shinyaku presented 4.5-year clinical follow-up data at the 2026 MDA Clinical & Scientific Conference [9]. The expected regulatory pathway follows the template Sarepta and NS Pharma established for prior PMO exon skippers: accelerated approval based on dystrophin restoration measured by Western blot in muscle biopsy, with confirmatory Phase 3 for functional benefit as a post-marketing requirement. NS Pharma walked this exact path with viltolarsen in 2020 [6]. Because brogidirsen is co-sponsored by NCNP and the Phase 1/2 was conducted in Japan, a parallel PMDA development track is running; specific Japanese regulatory milestones (PMDA filing status, sakigake or conditional approval) are not publicly confirmed in English-language disclosures. Public timing on US Phase 2 topline is not disclosed, but with the trial active-not-recruiting and an extension study already running, readout could land in the 2026-2027 window [3][4]. Nippon Shinyaku (TSE: 4516) is the ultimate parent and reports viltolarsen sales in Japanese filings; brogidirsen has not yet appeared as a named revenue product in Nippon Shinyaku disclosures.

DMD is caused by mutations in the dystrophin gene, the largest gene in the human genome. Dystrophin is a protein that acts like a shock absorber, physically linking a muscle fiber's inner cytoskeleton to the outer membrane (the sarcolemma). Without functional dystrophin, muscle cells tear themselves apart during ordinary contraction. Boys with DMD progressively lose muscle strength, typically stop walking by age 12, and die of cardiac or respiratory failure in their 20s or 30s. Most DMD mutations are out-of-frame deletions that scramble the reading frame downstream of the deletion, so no protein is made at all. Brogidirsen is a dual-targeting synthetic piece of RNA-like material (two directly connected 12-mer phosphorodiamidate morpholino oligomers, a modified nucleic acid backbone that resists enzymatic degradation) that binds to dystrophin pre-mRNA and hides exon 44 from the spliceosome (the molecular machine that cuts and re-joins RNA segments) [1][2][9]. When the spliceosome skips exon 44, the reading frame is restored in patients whose deletions create an out-of-frame junction that exon 44 skipping can repair, most commonly deletions of exon 45 alone, exons 43-45, or exons 45 through 47-54 [1]. The result is a shortened but partially functional dystrophin. Genetic validation comes from Becker muscular dystrophy patients, who carry naturally occurring in-frame deletions that yield the same kind of shortened dystrophin and often walk into their 40s or beyond. The genetic case is strong. Historically the practical question, unresolved after four approved exon skippers, was whether ASO-induced dystrophin restoration could reach the roughly 15-20% threshold that BMD biology suggests is clinically meaningful [1]. Brogidirsen Phase 1/2 data are the first PMO exon-skipping results to plausibly clear that bar [9].

NCT05996003 is a Phase 2, open-label, single-arm, multicenter study of brogidirsen delivered by weekly IV infusion in ambulant boys aged 4 to under 15 with DMD due to exon 44-amenable mutations [3]. Enrollment target is n=20, currently active not recruiting. Primary endpoint is safety and tolerability (adverse events and adverse drug reactions). Secondary endpoints described in the published Phase 1/2 protocol include dystrophin protein quantification by Western blot in pre- and post-treatment muscle biopsies, and functional measures such as the North Star Ambulatory Assessment, time-to-stand from supine, 10-meter run/walk time, and 6-minute walk distance [2]. An extension study (NCT05135663, n=6) is running to gather longer-term data, and the completed Phase 1/2 exploratory study (NCT04129294, n=6, sponsored by NCNP) supplied dose-finding, safety, and the pivotal Phase 1 dystrophin readout: mean dystrophin at 24 weeks reached 16.63% of normal at 40 mg/kg and 24.47% of normal at 80 mg/kg by Western blot [4][5][9]. Open-label single-arm design is the norm for this class because the addressable population is small (perhaps 300-500 US patients amenable to exon 44 skipping) and placebo-controlling children with a progressive fatal disease is ethically difficult. The weakness is that without a concurrent control, apparent functional stabilization cannot be cleanly separated from natural history variability, and the DMD field has been burned by open-label data before. Sarepta's eteplirsen accelerated approval in 2016 was granted over the objections of FDA's own review team, in part because the historical control comparison was contested. FDA has become more cautious about single-arm accelerated approvals since then.

Our model estimates a 18% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 34%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk has partially resolved on the upside. Phase 1/2 dystrophin restoration of 16-24% of normal at week 24 [9] is the strongest PMO biopsy result reported to date and reduces the 'nothing works above 5%' overhang that has dogged the class. The remaining efficacy question is whether Phase 2 replicates the Phase 1/2 signal in a larger cohort and whether functional measures track the biochemistry. Safety risk is moderate. The PMO class has been broadly well tolerated, and brogidirsen has not raised class-atypical signals in disclosed data; weekly IV infusion for years is still a substantial patient burden, and thrombocytopenia and renal signals (proteinuria, elevated cystatin C) have appeared with related ASO chemistries at higher doses. Regulatory risk has grown. FDA's willingness to accept dystrophin surrogate for accelerated approval has been repeatedly tested, and post-Aduhelm the agency is under pressure to demand cleaner functional data; that said, breakthrough therapy designation suggests FDA views the Phase 1 signal as substantial. Commercial risk is structural. The exon 44-amenable population is roughly 6-8% of DMD, translating to about 300-500 US patients [1]. Viltolarsen wholesale acquisition cost is around $700K per year, so peak US sales for brogidirsen likely cap under $300M annually even with strong penetration. Displacement risk from gene therapy is real but has shifted: Sarepta's Elevidys received traditional approval in June 2024 for ambulatory DMD patients aged 4 and older and accelerated approval for non-ambulatory patients, but the non-ambulatory indication was removed from the label in November 2025 following acute liver injury deaths [7]. Net effect: gene therapy still competes for the ambulatory exon-skipper pool, but the non-ambulatory patient population that ASOs could still serve has expanded relative to the 2024 outlook. Avidity's del-zota (formerly AOC 1044) in the same exon 44 population has already raised the class ceiling on dystrophin restoration to 25% net (~54-58% of normal total) [12][13]; brogidirsen must show functional benefit, not just competitive biopsy numbers, to hold value.

Worth watching, upgraded urgency after Phase 1/2 results. The Phase 1/2 biopsy data (16-24% of normal at week 24) [9] is the first PMO result to plausibly clear the Becker-inferred threshold of clinical relevance, and the 4.5-year follow-up presented at 2026 MDA suggests durability. The Phase 2 readout (NCT05996003) should confirm the biopsy signal at n=20 and provide the first meaningful functional trajectory (North Star Ambulatory Assessment, 10-meter run time, time-to-stand). If Phase 2 dystrophin lands in the 15-25% band with credible functional stabilization vs. natural history, brogidirsen is a strong accelerated approval candidate and the class economics reprice upward. If the Phase 1 signal does not replicate, the asset falls back into the ambiguous-benefit bucket that has capped prior PMOs. Check back when Nippon Shinyaku or NS Pharma announces Phase 2 topline, plausibly in the 2026-2027 window given active-not-recruiting status and typical DMD biopsy timelines. The head-to-head comparator to track is Avidity's del-zota, whose EXPLORE44 program has reported higher absolute dystrophin numbers (25% net production increase, 54-58% of normal total) [12][13] but with a more complex delivery chemistry and higher COGS than a naked PMO; the strategic question is whether Avidity's advantage is large enough to justify the delivery-conjugate premium, or whether brogidirsen's simpler chemistry with a solid biopsy signal wins on regulatory precedent and manufacturing. NS Pharma sits inside Nippon Shinyaku (TSE: 4516), which provides regulatory adult supervision and covers the funding gap. Milestone-driven asset; the next material price move is the Phase 2 biopsy readout.